The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Establishing the clinical benchmark of azacitidine in patients with MDS
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the aims and findings of a recently published systematic review of outcomes for patients with higher-risk myelodysplastic syndromes (MDS) treated with azacitidine in clinical trials. The pivotal AZA-001 trial (NCT00071799), which provided the supporting evidence for the use of frontline azacitidine in high-risk MDS, achieved a median overall survival (mOS) of 24 months. However, the results achieved in subsequent trials have been highly variable and real-world survival data is consistently shorter than that seen in AZA-001. The lack of a clear clinical benchmark has made it challenging to determine the contribution of novel therapies added to azacitidine. To address this, the results from 237 studies were pooled which found a mOS of around 18 months. The study also explored potential surrogate endpoints but a robust parameter that correlated with OS was not found. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
